HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eary, J. F. Articles by Bernstein, I. D. Search for Related Content PubMed PubMed Citation Articles by Eary, J. F. Articles by Bernstein, I. D.

Imaging and Treatment of B-Cell Lymphoma

Departments of Radiology, Division of Nuclear Medicine, Medicine and Pediatrics, University of Washington Medical Center
Fred Hutchinson Cancer Research Center, First Hill Diagnostic Inc., Seattle, Washington
Battelle Pacific Northwest Laboratories, Richland, Washington
Department of Medicine, Stanford University, Stanford, California
IDEC Pharmaceuticals Corp., Mountain View, California

Correspondence: For reprints contact: Janet F. Eary, MD, University of Washington Hospital, Division of Nuclear Medicine RC-70, 1959 Pacific St., Seattle, WA 98195.

ABSTRACT

Ten patients with non-Hodgkin's lymphoma have been evaluated as candidates for experimental radioimmunotherapy and five of those patients have been treated with a single high dose of iodine-131-(¹³¹I) labeled anti-pan B-cell antibodies. The evaluation protocol involved collecting biodistribution data by quantitation of gamma camera images and by tumor biopsy from trace labeled doses of antibody, to estimate the relative radiation dose delivered to normal organs and tumor sites. Each patient received up to three escalating mass doses (0.5 mg/kg, 2.5 mg/kg, and 10.0 mg/kg) of radioiodinated antibody for determination of the antibody amount that yielded the most favorable biodistribution for treatment. The millicuries of ¹³¹I-labaled to the optimal antibody dose for therapy was selected to deliver 1,000 rads (three patients) or 1,500 rads (two patients) to normal uninvolved organs. Because severe bone marrow toxicity was expected, all patients had their bone marrow cryopreserved prior to entry into the study. This report details the methods and results of quantitative imaging, biodistribution data collection, and absorbed radiation dose estimation in patients with lymphoma receiving high level radioimmunotherapy with ¹³¹I-labeled antibodies.

This article has been cited by other articles:

				J. G. Rajendran, A. K. Gopal, D. R. Fisher, L. D. Durack, T. A. Gooley, and O. W. Press Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose J. Nucl. Med., May 1, 2008; 49(5): 837 - 844. [Abstract] [Full Text] [PDF]

				X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood, October 1, 2007; 110(7): 2569 - 2577. [Abstract] [Full Text] [PDF]

				A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF]

				J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Blood, March 1, 2006; 107(5): 2184 - 2191. [Abstract] [Full Text] [PDF]

				A. O. Schaffland, F. Buchegger, M. Kosinski, C. Antonescu, C. Paschoud, C. Grannavel, R. Pellikka, and A. B. Delaloye 131I-Rituximab: Relationship Between Immunoreactivity and Specific Activity J. Nucl. Med., October 1, 2004; 45(10): 1784 - 1790. [Abstract] [Full Text] [PDF]

				J. G. Rajendran, D. R. Fisher, A. K. Gopal, L. D. Durack, O. W. Press, and J. F. Eary High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes J. Nucl. Med., June 1, 2004; 45(6): 1059 - 1064. [Abstract] [Full Text] [PDF]

				A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Blood, October 1, 2003; 102(7): 2351 - 2357. [Abstract] [Full Text] [PDF]

				G. Sgouros, S. Squeri, A. M. Ballangrud, K. S. Kolbert, J. B. Teitcher, K. S. Panageas, R. D. Finn, C. R. Divgi, S. M. Larson, and A. D. Zelenetz Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response J. Nucl. Med., February 1, 2003; 44(2): 260 - 268. [Abstract] [Full Text] [PDF]

				J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390. [Abstract] [Full Text] [PDF]

				K. Sjogreen, M. Ljungberg, and S.-E. Strand An Activity Quantification Method Based on Registration of CT and Whole-Body Scintillation Camera Images, with Application to 131I J. Nucl. Med., July 1, 2002; 43(7): 972 - 982. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				A. K. Gopal, J. G. Rajendran, S. H. Petersdorf, D. G. Maloney, J. F. Eary, B. L. Wood, T. A. Gooley, S. A. Bush, L. D. Durack, P. J. Martin, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood, May 1, 2002; 99(9): 3158 - 3162. [Abstract] [Full Text] [PDF]

				G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. ter Linden, G. A. van Dongen, and C. F. Molthoff Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN J. Nucl. Med., March 1, 2001; 42(3): 509 - 519. [Abstract] [Full Text]

				O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood, November 1, 2000; 96(9): 2934 - 2942. [Abstract] [Full Text] [PDF]

				D. C. Matthews, F. R. Appelbaum, J. F. Eary, D. R. Fisher, L. D. Durack, T. E. Hui, P. J. Martin, D. Mitchell, O. W. Press, R. Storb, et al. Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome Blood, August 15, 1999; 94(4): 1237 - 1247. [Abstract] [Full Text] [PDF]

				O. W. Press, J. F. Eary, F. R. Appelbaum, P. J. Martin, C. C. Badger, W. B. Nelp, S. Glenn, G. Butchko, D. Fisher, B. Porter, et al. Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support N. Engl. J. Med., October 21, 1993; 329(17): 1219 - 1224. [Abstract] [Full Text]